

Applicants: Bover Fuentes, et al.
Serial No.: Unassigned
Filing Date: Herewith
Docket No.: 976-25 PCT/US
Page 3

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces the listing of claims in the application.

Listing of Claims:

CLAIMS

**~~COMBINATIONS OF GROWTH REGULATING FACTORS AND HORMONES
FOR THE TREATMENT OF NEOPLASIA~~**

What is claimed is:

1- (Currently Amended) ~~A Pharmaceutical~~ pharmaceutical combinations combination for the treatment of neoplasia through simultaneous, separate, or sequential administration, comprising a compound A and B, wherein A is ~~and B are~~ selected from the group of molecules consisting in of:

~~A:~~

- ~~a.1.~~ GnRH, or its analogues, or anti-GnRH antibodies, or GnRH receptor (GnRH-R), or its mutated variants, or derivative peptides, or anti-GnRH-R antibodies, coupled or not to an immunopotentiating carrier protein;
- ~~a.2.~~ ~~Natural~~ natural or recombinant gonadotropins, or their analogues, or their mutated variants, coupled or not to an immunopotentiating carrier protein, hypophyseal anti-gonadotropin antibody, their Fags, scFV fragments, humanized or not;
- ~~a.3.~~ ~~Hypophyseal Gonadotropin~~ hypophyseal gonadotropin receptors, or their mutated variants, or derivative peptides, coupled or not to an immunopotentiating carrier protein; and
- ~~a.4.~~ ~~Hypophyseal Gonadotropin~~ hypophyseal gonadotropin anti-receptor antibodies, their Fabs, scFV fragments, humanized or not;

~~B:~~

and wherein B is selected from the group of molecules consisting of:

- ~~b.1.~~ ~~Natural~~ natural or recombinant EGF or its mutated variants, or derivative peptides, or EGF mimetic peptides, or EGF analogues, coupled or not to an immunopotentiating carrier protein;
 - ~~b.2.~~ ~~Anti-EGF~~ anti-EGF antibodies, their FabsscFV fragments, humanized or not;
 - ~~b.3.~~ EGF receptor (EGF-R), or its mutated variants, or derivative peptides coupled or not to an immunopotentiating carrier protein;
 - ~~b.4.~~ ~~Anti-EGF~~ anti-EGF receptor antibodies, their Fabs, scFV fragments, humanized or not;
 - ~~b.5.~~ ~~Natural~~ natural or recombinant VEGF or mutated variants, or derivative peptides, or VEGF mimetic peptides, or VEGF analogues, coupled or not to an immunopotentiating carrier protein;
 - ~~b.6.~~ ~~Anti-VEGF~~ anti-VEGF antibodies, their Fabs, scFV fragments, humanized or not;
 - ~~b.7.~~ VEGF receptors, or mutated variants, or derivative peptides from VEGF receptors, coupled or not to an immunopotentiating carrier protein;
 - ~~b.8.~~ ~~Anti-VEGF~~ anti-VEGF receptor antibodies, their Fabs, scFV fragments, humanized or not;
 - ~~b.9.~~ ~~Natural~~ natural or recombinant TGF or mutated variants, or derivative peptides, or TGF mimetic peptides, or TGF analogues, coupled or not to an immunopotentiating carrier protein;
 - ~~b.10.~~ ~~Anti-TGF~~ anti-TGF antibodies, their Fabs, scFV fragments, humanized or not; and
 - ~~b.11~~ TGF receptor (TGF-R), or mutated variants, or derivative peptides coupled or not to an immunopotentiating carrier protein.
- 2- (Currently Amended) ~~Combinations~~ A combination according to claim 1, wherein the A and B group of molecules are coupled to the immunopotentiating carrier protein by conjugation or the formation of chimeric proteins.

- 3- (Currently Amended) ~~Combinations~~ A combination according to ~~claims claim~~ claim 1 and 2, wherein the GnRH analogue peptide has sequence pGlu-His-Trp-Ser-Tyr-Pro-Leu-Arg-Pro-Gly, coupled to an immunopotentiating carrier protein.
- 4- (Currently Amended) ~~Combinations~~ A combination according to ~~claims claim~~ claim 1 and 2, wherein the immunopotentiating carrier protein is selected from *Neisseria meningitides* P1 and P64 outer membrane proteins.
- 5- (Currently Amended) ~~Combinations~~ A combination according to ~~claims claim~~ claim 1 and 2, wherein the immunopotentiating carrier protein is a Tetanic Toxoid (TT) T helper epitope.
- 6- (Currently Amended) ~~Combinations~~ A combination according to ~~claims claim~~ claim 1 and 2, wherein the conjugated chimeric protein is one of the following variants:
 - a) GnRH bound to a carrier protein and to EGF₁₋₃
 - b) GnRH bound to a carrier protein and to VEGF₁₋₃
 - c) GnRH bound to a carrier protein and to TGF₁₋₃
 - d) GnRH bound to a carrier protein, to EGF and TGF₁₋₃ or
 - e) GnRH bound to a carrier protein, to VEGF and EGF.
- 7- (Currently Amended) A method for the generation of combined immune response comprising treatment with ~~one of the therapeutic combinations~~ combination ~~defined in any claims from~~ according to claim 1 to 6.
- 8- (Currently Amended) A method according to claim 7, wherein the ~~combinations~~ combination can be applied simultaneously, separately, or sequentially.